The Candida albicans ERG27 gene which encodes the 3-keto reductase enzyme required for sterol C-4 demethylation was isolated and found to encode a 349 amino acid protein that is 60% identical at the amino acid level to the Saccharomyces cerevisiae Erg27p. A C. albicans erg27 null was created in a strain containing an integrated ERG27 rescue cassette under the control of the pMAL2 inducible promoter. The C. albicans erg27 strain was able to grow only in the presence of maltose indicating that the ERG27 gene is essential. The C. albicans erg27 null showed complete loss of both 3-keto reductase and oxidosqualene cyclase (Erg7p) activities compromising all sterol synthesis. These results suggest that Erg27p inhibitors might be effective antifungals. To explore ERG27 regulation, an erg11 null strain was generated. C. albicans erg6 and erg24 mutants were also employed along with the inhibitors, itraconazole and zaragozic acid A, to characterize ERG27 expression using Northern analysis. Expression was increased two-to fourfold in erg11, erg6 and erg24 backgrounds. However, itraconazole which targets Erg11p (lanosterol demethylase) increased ERG27 expression 10-fold and zaragozic acid A which targets the Erg9p (squalene synthase) increased ERG27 expression fivefold. The azole and erg11 results support other observations that azoles may affect non-sterol targets.
Introduction
The incidence of fungal infections has been on the rise for a number of years with various circumstances acting as contributing factors. Among them have been the expanded and prolonged use of the currently available antifungal compounds, invasive medical procedures, and therapies and diseases that compromise the immune response [1, 2] . Over-utilization of current antifungals compounds, especially in cases where the immune system responds inadequately, has acted as a strong selective pressure for the increased incidence of resistant forms of pathogenic organisms.
Although other classes of antifungal agents are currently available and new ones are in development, the azoles remain the major class of antifungal compounds used to treat human infection. The azoles are fungistatic drugs that inhibit the C-14 sterol demethylase encoded by the ERG11 gene [3] (Fig. 1) . Mechanisms of resistance to azoles have been shown to result from the increased expression of multi-drug transporters [4, 5] , mutations in the ERG11 gene [6] , and increased expression of the ERG11 gene [7] . The latter mechanism of increased gene expression has been reported as a general response of fungi to ergosterol inhibitors and has been noted in many of the genes whose products function in the ergosterol biosynthetic pathway [8, 9] .
A limited number of sites for inhibition of ergosterol biosynthesis have been identified for the development of effective antifungal compounds. This restriction, coupled with the emergence of increasing drug resistance to available compounds has resulted in a real need for new classes of antifungal compounds [10] .
The ergosterol biosynthetic pathway includes several enzymatic steps that may be excellent sites for the development of novel classes of antifungal compounds. To be a suitable candidate for inhibition, the biosynthetic step should be required for growth and/or pathogenicity. To explore these characteristics, the genes encoding each enzyme have been isolated and characterized in Saccharomyces cerevisiae, with the resulting information being used to repeat the procedure in Candida albicans, a common human fungal pathogen. The specific sterol requirements in these two organisms can differ thus requiring that each of the homologous genes be characterized. The ERG11 and ERG24 (encodes the sterol C-14 reductase) genes have been found to be essential in S. cerevisiae [11 Á/14] but not in C. albicans [15 Á/17] . In contrast, the ERG6 gene encoding the sterol methyl transferase has been found to be non-essential in both organisms [18, 19] while the ERG25 gene encoding the C-4 sterol methyl oxidase [20 Á/22] and the ERG26 gene encoding the C-3 sterol dehydrogenase (C-4 carboxylase) [23, 24] have been found to be essential in both organisms.
The final gene whose product participates in the C-4 sterol demethylation (along with Erg25p and Erg26p) is the ERG27 gene encoding the sterol 3-keto reductase. Gachotte et al . [25] demonstrated that loss of S. cerevisiae Erg27p also results in a very marked diminution of lanosterol, the product of oxidosqualene cyclase activity (Erg7p). Therefore, the loss of Erg27p in S. cerevisiae results in the loss of the entire sterol pathway and is attributable to Erg27p being required to prevent digestion of Erg7p as it is transported to the lipid particles [26] . A fourth protein involved in C-4 demethylation is Erg28p [27] which has no pathway enzymatic function but plays a role in facilitating the functions of Erg26p and Erg27p, presumably by tethering these enzymes into a multi-enzyme complex in the ER [28] . S. cerevisiae erg28 nulls are nonauxotrophic and produce ergosterol but also accumulate sterol intermediates like those seen in erg26 and erg27 nulls [27] . The ERG28 gene is highly conserved across species and the C. albicans version is currently under study.
The three enzymes involved in the removal of the two C-4 methyl groups provide significant potential for the development of novel antifungal agents. Recently an effective Erg25p inhibitor has been isolated from a Penicillium broth [29] . Based on the characteristics of the erg27 phenotype in S. cerevisiae, where a block at ERG27 results in an inability of the pre-sterol pathway step at ERG7 to function, Erg27p may have the best potential of the three as a target for development of a fungicidal drug targeting the sterol pathway.
Based on the phenotype of the S. cerevisiae erg27 mutant, it was of interest to determine whether a mutation in the C. albicans ERG27 gene would likewise result in a block prior to lanosterol formation. If so, this would make inhibition of this step a priority for the development of antifungal agents since inhibitors of Erg27p would be lethal to fungal cells since membrane sterol is essential for viability. In addition, delineation of some of the regulatory features of C-4 demethylation in C. albicans would be of interest from the basic perspective of pathway dynamics as well as the applied perspective of predicting whether up-regulation of ERG27 expression could be a resistance mechanism that may emerge to Erg27p inhibitors. Analysis of ERG27 gene expression in the presence of azole antifungals, other sterol inhibitors, and in particular in an erg11 null strain would also be of wide interest in delineating general pathway responses to perturbation.
Materials and methods

Strains and plasmids
Saccharomyces cerevisiae strain SDG100 (Mat a upc2 ade2 his3 ura3-52 erg27-1 ) is described in Gachotte et al . [25] . C. albicans strain BWP17 (ura3D::limm434/ ura3 D::limm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG ) was obtained from A. Mitchell [30] . C. albicans strains CAI4 (ura3D::limm434/ura3D::limm434 ) was obtained from W. Fonzi [31] . C. albicans erg6 and erg24 mutant strains, constructed in our lab, are described elsewhere [17, 19] . Escherichia coli strain DH5a was used to amplify plasmid DNA. Plasmids pGEM-URA3, pGEM-HIS1 and pRSARG4DSpeI were obtained from A. Mitchell [30] . Plasmid pDBI52 was obtained from C. Kumamoto [32] while the C. albicans genomic library 655 (generated from C. albicans ATCC 56844) was obtained from S. Scherer [33] .
Media and growth
E. coli cultures were grown in Luria broth (LB). Solid LB media were made by adding agar (Difco) at 20 g/l. Ampicillin was added after autoclaving at 60 mg/ml for plasmid selection. Cultures were grown at 378C. S. cerevisiae and C. albicans were grown on either CSM (Complete Synthetic Medium) or YPAD, an enriched medium. CSM (Qbiogene, Carlsbad, CA, USA) contained 0.17% yeast nitrogen base without amino acids (Difco), 0.5% ammonium sulfate, 2% D-glucose and a mixture of amino acids plus adenine (360 mg/l) and uridine (80 mg/l). CSM media lacking specific nutrients were used in selection. YPAD was composed of 1% Bacto yeast extract, 2% Bacto peptone, and 2% Dglucose plus adenine (360 mg/l) and uridine (80 mg/l). Maltose was substituted for glucose at 2%. Ergosterol, when needed, was added to autoclaved and cooled media at 20 mg/l to rescue erg27 mutants in S. cerevisiae. S. cerevisiae cultures were grown at 308C and C. albicans cultures were grown at 30 or 378C. Itraconazole was provided by Janssen Pharmaceutical. Stocks at 2 mg/ml were made in DMSO. Zaragozic acid A was obtained from Merck and stocks were made in distilled water at 5 mg/ml. For anaerobic growth, the Gas Pak System (BBL Microbiology Systems, Cockeysville, MD, USA) was used. Itraconazole-treated cells were grown in 0.2 mg/l itraconazole (results in 50% normal growth rate) to an OD 660 of 0.7 Á/1.0. The itraconazole concentration was raised to 1 mg/l for 6 h and the cells were harvested. Cells were treated with 30 mg/l zaragozic acid A until a concentration at OD 660 of 0.7 Á/1.0 was obtained and harvested.
Transformations
Escherichia coli DH5a cells were transformed using standard transformation protocols [34] .
The transformation protocol for S. cerevisiae has been previously described [35] . C. albicans transformations were carried out as previously described [30] .
DNA sequencing
DNA sequencing was performed at the Biochemistry Biotechnology Facility (BBF) in the Indiana University School of Medicine Indianapolis, IN, USA). Once initial sequence data were obtained using primers T3 and T7, new primers were designed to facilitate acquisition of additional DNA sequence data. All primers for sequencing were purchased through Sigma Á/Genosys (The Woodlands, TX, USA).
PCR
PCR reactions were carried out on a Perkin Elmer GeneAmp2400 thermocycler with the following parameters: 948C for 3 min for the first denaturation of the DNA template, followed by 30 Á/40 cycles with three identical steps: 948C for 45 s, 558C (or 58C below primer annealing temperature) for 30 Á/60 s for primers to anneal to denatured DNA, and 728C for elongation (for 2.5 Á/3.5 min depending upon length of expected DNA product), followed by 728C for 10Á/15 min to complete all possible reactions. To avoid mispriming, touch down PCR was applied. Initially, the annealing temperature was maintained at the same temperature as the primer's denaturing temperature for two cycles, and gradually dropped 1Á/28C every two cycles until an annealing temperature 58C below the primer's melting temperature was reached. The PCR reaction was then run for another 25 Á/35 cycles at the final annealing temperature.
Two kinds of thermostable DNA polymerases were used. Taq DNA polymerase in Buffer B (Promega, Madison, WI, USA) was mainly used to screen genetic constructions or genetic insertions. Reaction buffer (50 mmol/l KCl, 10 mmol/l Tris-HCl, pH 9.0, 0.1% Triton X-100) plus 1.5 Á/2.0 mmol/l MgCl 2 and 1.25 U polymerase was used. A second polymerase, Expand High Fidelity Taq polymerase (EHF Taq ) (Roche, Indianapolis, IN, USA) at 2.6 U per reaction, was used to amplify selectable marker genes. Reaction 
PCR primers
The primers used in this study are listed in Table 1 .
Sterol analysis
Sterols were isolated as previously described [36] and analyzed by gas chromatography (GC). A HP5890 series II equipped with the Hewlett-Packard CHEM-STATION software package was used to analyze sterol content. The capillary column (DB-1) was 15 m)/0.25 mm )/0.25-mm film thickness (J&W Scientific, Folsom, CA, USA) and was programmed from 1958C to 2808C (1 min at 1958C, then an increase at 208C/min to 2408C, followed by 28C/min until the final temperature of 2808C was reached). The linear velocity was 30 cm/s using nitrogen as the carrier gas, and all injections were run in the splitless mode.
Gas chromatography/Mass spectrometry (GC/MS) analyses of sterols were done using a Thermoquest Trace 2000 gas chromatograph interfaced to a Thermoquest Voyager mass spectrometer. The GC separations were done on a fused silica column, DB-5MS, 20 m )/0.18 mm )/0.18-mm film thickness (J&W Scientific). The injector temperature was 1908C. The oven temperature was programmed to remain at 1008C for 1 min followed by a temperature ramp of 6.08C/min to a final temperature of 3008C. The final temperature was held for 25 min. Helium was the carrier gas with a linear velocity of 50 cm/s in the splitless mode. The mass spectrometer was in the electron impact ionization mode at an electron energy of 70 eV, an ion source temperature of 1508C, and scanning from 40 to 850 atomic mass units at 0.6 s intervals.
Spot-plate growth test
Yeast strains were inoculated into 50 ml of liquid media and incubated at 308C in a shaker at 200 r.p.m. overnight. Cell concentrations were determined using a hemacytometer and diluted to give a series of cell concentrations of 2 )/10 7 , 2)/10 6 , 2)/10 5 and 2)/10 4 cells/ml. 5 ml of each concentration was added onto solid media to give a series of spots containing 1)/10 5 Á/1)/10 2 cells.
Rescue cassette for the erg27 phenotype
Since the ERG27 gene has been shown to be essential in S. cerevisiae [25] , it is likely to be essential in C.
albicans. The disruption of the second copy of the ERG27 gene would thus result in a non-viable cell. Since C. albicans cannot utilize exogenous sterol under aerobic or anaerobic conditions [37] , a rescue cassette containing a third copy of the ERG27 gene under the control of the inducible pMAL2 promoter [28] was constructed. The ERG27 ORF was amplified from BWP17 genomic DNA using primers 27-ampF and 27-ampR ( Table 1) . The former contained an Eco RV site at the 5? end and the latter contained a Xba I site at the 5? end. The 1.3-kb products were ligated into pDBI52 after both had been digested simultaneously with Eco RV and Xba I. A transformant with the correct ligations was isolated and designated pNJ01. The plasmid pNJ01 was linearized at the Bam HI site in the ADE2 marker and used to transform NJ32. Transformants were selected on CSM-arg-ura'/ade.
Disruption of the ERG27 alleles
Both copies of the ERG27 gene were disrupted using a cassette comprised of short homology regions of the ERG27 gene flanking a selectable marker [30] . The PCR primers 27-ARGF and 27-ARGR (Table 1) consisting of 50Á/60 bases of the ERG27 gene and a short plasmid sequence were constructed to amplify the ARG4 marker on pRS-ARG4DSpe I. The resulting 2.4-kb products were used to transform C. albicans strain BWP17 and transformants were selected on CSM-arg'/ade'/uri. Primers 27-HISF and 27-HISR containing 50 Á/60 bp of ERG27 sequence and plasmid sequence were used to amplify the HIS1 gene on pGEM-HIS1. The ERG27 sequences for the second disruption were distinct from those used for the ARG4 amplified DNA employed in the disruption of the first allele to eliminate the possibility of insertion at the first disruption site. The PCR products were used to transform the ERG27 heterozygote containing the rescue cassette, and transformants were selected on CSM-arghis'/ade with maltose as the carbon-energy source. Disruptions of both ERG27 alleles were confirmed by PCR using appropriately designed primers.
Disruption of the ERG11 gene of C. albicans
PCR primers ERG11-URAF and ERG11-URAR (Table 1) containing 50Á/60 bases of the ERG11 gene and a short plasmid sequence were used to amplify the URA3 gene on plasmid pGEM-URA3. The resulting 1.4-kb products were used to transform C. albicans BWP17 and transformants were selected on CSMura. Confirmation of the first disruption was accomplished by using primers ERG11-disF and ERG11-disR (Table 1) which were designed to amplify a 1.4-kb 
Sterol biosynthesis in C. albicans 465 fragment in the wild type allele and a 2.1-kb fragment in the URA3 -disrupted allele. The primers were designed within the distal ends of the ERG11 gene such that any ERG11 sequence in the genome would be amplified. Since the ERG11 gene has been shown to be non-essential in C. albicans [15, 16] , the second allele could be disrupted directly. The heterozygote was plated on YPAD supplemented with 15 mg/l nystatin to select for those cells that had undergone mitotic recombination and no longer produced ergosterol. Homozygous erg11 mutants were confirmed as such by PCR using primers ERG11-disF and ERG11-disR.
RNA isolation
RNA extraction was performed using a standard protocol [30] .
Northern blotting
Isolated RNA was resolved in 1.5% agarose, formaldehyde denaturing gels and then transferred to the membrane. Random radio-labeled probes were made using the redi prime TM II Kit (Strategene, Cedar Creek, TX, USA) and PCR-generated DNA template from within the ERG27 ORF generated by standard PCR using primers listed in Table 1 and pIU1717 (this publication). Hybridization was done in QuikHyb buffer (Strategene) at 658C for 1 h. The membrane was washed with 1 )/SSC containing 0.1% SDS at 688C until only specific probe was detected using a RPI GM-2 Rad-Monitor. Results were obtained by exposing a Molecular Dynamics Storage Phosphor screen to hybridized blots and developing on a Molecular Dynamics Strom 840 at 200-nm resolution. ERG27 mRNA levels were determined relative to the constitutively expressed actin gene (ACT1 ).
Nucleotide sequence accession numbers
The GenBank accession numbers for the ERG27 sequences from S. cerevisiae and C. albicans are NC 001144.2 and AY 140908, respectively.
Results
Isolation and characterization of the C. albicans ERG27 gene Figure 1 depicts the ergosterol biosynthetic pathway and points of inhibitor action relevant to this study. The C. albicans ERG27 gene was isolated by complementation of a S. cervisiae erg27 mutant (strain SDG100) with the C. albicans genomic library 655. This procedure has been used to isolate several other genes of the C. albicans sterol pathway [17, 19, 22, 24] .
Transformed cells were plated onto CSM-ura'/ergosterol plates and incubated at 308C under anaerobic conditions for 3 days. More than 10 000 resulting colonies were replica plated onto CSM-ura medium plates and incubated at 308C under aerobic conditions for 2 days. Colonies able to grow without ergosterol supplementation were analyzed by GC. The sterol profile of S. cerevisiae SDG100 (erg27 ) grown with limited ergosterol supplementation is shown (Fig. 2) along with profiles of a C. albicans ERG27 transformant of SDG100 and a S. cerevisiae wild type. The sterol profile of the transformant is identical to that of the wild type indicating that the plasmid contains a C. albicans sequence that fully restores ergosterol synthesis. Elimination of the URA ' plasmid by treatment with 5-fluoroorotic acid (FOA) confirmed that the plasmid-borne sequence from C. albicans was responsible for the wild type sterol profile.
From among eight colonies analyzed, a plasmid (pIU1717) which complemented erg27 null strains and contained a 2.7-kb insert was extracted and both strands sequenced using T3 and T7 primers. Further Fig. 2 The sterol profiles of a Saccharomyces cerevisiae erg27 mutant (SDG100) supplemented with low levels of ergosterol to allow growth, SDG100 complemented with a Candida albicans ERG27 , and a S. cerevisiae wild type. A, squalene; B, squalene epoxide; C, squalene dioxide; D, zymosterol; E, ergosterol; F, fecosterol; G, episterol; H, lanosterol. sequencing was accomplished using primers generated from revealed sequence. The putative C. albicans ERG27 open reading frame was comprised of 1041 bp predicting a polypeptide of 346 amino acids. The two CTG codons at positions 318 and 323 code for serine rather than leucine in C. albicans [38] . The ERG27 gene in S. cerevisiae had methionine and alanine at these positions, respectively [25] . In comparing this sequence with the Candida genomic sequence (10 )/ Contig, assembly 19), at the Stanford Genome Technology Center (www.sequence.stanford.edu/group/ candida), ten differences were noted but only four of these resulted in an amino acid change ( Table 2 ). The predicted amino acid sequence of the C. albicans ERG27 ORF shows 60% identity with the Erg27p sequence reported for S. cerevisiae [25] .
Creation of the erg27 null
Disruption of the first ERG27 allele was accomplished using the ERG27-ARG4 disruption cassette and confirmed by PCR using the primers 27-disF, 225 bp upstream of the ERG27 start codon, and 27-disR, 654 bp downstream of the ERG27 stop codon ( Table  1) . The primers amplified a 1.9-kb fragment for the ERG27 wild type allele and a 2.8-kb fragment for the disrupted allele. Fig. 3a shows the presence of the 1.9-kb fragment in the wild type while both bands were present in the heterozygote (NJ32). NJ32 produced a wild type sterol profile. All heterozygous isolates tested yielded similar results (data not shown). Following transformation of the heterozygote with the linearized rescue cassette containing the pMAL2-ERG27 construct, twelve resulting colonies were selected for PCR confirmation of integration at the ADE2 locus. The integration was too large (Â/ 9 kb) to confirm with a single set of primers so two sets of primers were designed (Table 1) . Primer ADE2F, located 40 bp upstream of the ADE2 start codon, and primer pMALR, from the middle of pMAL2 , were used to amplify 4.8-kb segment while primer pMALF, from the middle of pMAL2 , and primer ADE2R, from 189 bp downstream of the ADE2 stop codon, were used to amplify a 4.3-kb segment. Two isolates yielded the two predicted fragments and the results from one (NJ45) are shown in Fig. 3b . The same primers ( Table 1) that were used to verify the ARG4 disruption, for the first ERG27 allele, were used to confirm that the second ERG27 allele was disrupted. A 2.7-kb fragment was predicted to be amplified for erg27::HIS1 . Fig. 3c shows the presence of both the 2.8-kb band from the ARG4 -disrupted ERG27 allele and the 2.7-kb band from the HIS1 -disrupted ERG27 allele in NJ61. Five NJ61 isolates and control strains were spot-plate tested for growth on maltose and glucose media. All strains, wild type and heterozygous, grew well at all dilutions on both glucose and maltose media (Fig. 4a) . The one NJ61 isolate shown grew normally on maltose media but very poorly on glucose media (Fig. 4a) . Northern analysis of strain NJ61 determined that pMAL2 -ERG27 expression on glucose was minimal (4%) relative to that noted for maltose grown cells (Fig.  4b) . This low level of expression would predict a small accumulation of ergosterol in NJ61.
GC analysis of NJ61 grown on maltose and glucose showed a wild type sterol profile on the former and an erg27 profile on the latter (Fig. 5) . The sterol precursors (squalene, squalene epoxide, and squalene dioxide) that accumulated on glucose are the same intermediates produced by S. cerevisiae SDG100 when grown in the presence of low amounts of ergosterol. In the case of NJ61, the low amounts of ergosterol are the result of recombination of the ERG27 gene in a small number of cells to a locus where it is not regulated by pMAL2 . 
Candida albicans erg11 disruption
A particularly important consideration in evaluating erg gene expression would be the alterations involving the Erg11p. Since azoles, the major class of antifungal drugs, target Erg11p, an erg11 null strain was isolated by performing sequential disruptions of each ERG11 allele in a wild type strain. The disruption of the first ERG11 allele was confirmed by PCR that showed the presence of the predicted 1.4-kb wild type and 2.1-kb disrupted bands (Fig. 6 ) in the ERG11 heterozygote, erg11H5. Analysis of the sterol content (Fig. 7) showed a wild type profile indicating that there were no other ergosterol mutations present in the heterozygote. Following mitotic recombination in the heterozygote and selection on nystatin, several homozygous erg11 mutants were confirmed by PCR in which the 2.1-kb fragment of the disrupted erg11 was observed but not the 1.4-kb wild type fragment (Fig. 6a) . The erg11-disrupted strains generated here are the first nonclinical isolates of a C. albicans erg11 . Sterol analysis of the C. albicans erg11 strains (Fig. 7) indicated the presence of the predicted C-14 methyl sterols (24-methylene lanosterol {30%}, obtusifoliol {26%}, 14-methylergosta-8,24(28)-dien-3,6-diol {18%}, 14-methylfecosterol {15%}, and lanosterol plus some additional C14 methyl sterols {11%}) including significant levels of a C14 methylsterol diol ( Fig. 7 ; peak N). This profile is consistent with those reported for clinical isolates of erg11 [15, 16] . The profile also indicates that (i) there is no functional Erg11p activity present (only C14 methyl and methylene sterols accumulate; (ii) that a functional Erg3p is present (sterol diol is present); and (iii) that the ERG11 gene is not essential in C. albicans.
Northern analysis of C. albicans ERG27 expression
Based on the observation that lesions in the ergosterol pathway up-regulate expression of pathway genes [8, 9] , the expression of the C. albicans ERG27 was determined using Northern analysis. To this point, no systematic investigation of the regulation of any of the C-4 demethylation genes has been undertaken. To facilitate the analysis of ERG27 regulation, several steps in the pathway (Fig. 1) were selected for inhibition either by known inhibitors or by utilizing mutants defective at those steps. Steps upstream and downstream of Erg27p action and steps that are the target sites for important antifungal drugs were included (Fig. 1) . The isolation and sterol characterization of the C. albicans erg6 [19] and erg24 strains [17] have been reported elsewhere. Regulation of ERG27 in an erg11 background was also investigated using the erg11 null as well as itraconazole, an azole that inhibits the Erg11p. The azole treatment protocol was chosen to saturate the Erg11p in order to eliminate all enzyme activity as would be the case in null mutant. In addition, the early pathway step catalyzed by squalene synthase (Erg9p) was inhibited using zaragozic acid A. Figure 8a shows ERG27 expression levels following treatment with itraconazole and zaragozic acid A. Relative to the untreated wild type strain, itraconazole and zaragozic acid A result in ten-and fivefold increases in ERG27 expression, respectively. In a background where both ERG11 alleles have been disrupted, a condition that would produce the same sterol profile as itraconazole treatment [3] , ERG27 expression increases three-to fourfold. Strains with disruptions in the upstream ERG24 gene and the downstream ERG6 gene (Fig. 1) show increases in ERG27 expression in the twofold range (Fig. 8b) .
Discussion
In order to determine if the ERG27 gene is essential in C. albicans both copies were disrupted. Although disruption of ERG27 in the haploid S. cerevisiae has shown this gene to be essential, there are significant differences in sterol requirements between the two organisms necessitating this verification. A prime example is the ERG11 gene that encodes the C-14 demethylase. In S. cerevisiae the erg11 phenotype results in no growth unless suppressed by a mutation in the downstream ERG3 gene [39, 40] while in C. albicans the erg11 mutant is viable [15] . Similarly, the ERG24 gene has been found to be essential in S. cerevisiae [12 Á/14] but not in C. albicans [17] .
The sterol profile in Fig. 2 shows that ergosterol synthesis has been restored in a S. cerevisiae erg27 mutant by complementation with a C. albicans genomic library. The complementing DNA sequence has been confirmed as the ERG27 gene by comparison with the S. cerevisiae ERG27 sequence. The C. albicans ERG27 gene encodes a polypeptide that is 60% identical to the Erg27p reported for S. cerevisiae. The sequence of the C. albicans ERG27 gene varies from that reported in the C. albicans sequence database (10 )/ Contig, assembly 19) by ten nucleotide substitutions (Table 2) . Six do not change the encoded amino acid while the remaining four lead to amino acid substitutions that do not affect function. There are no identifiable phenotypes, including altered sterol phenotype, to distinguish this wild type C. albicans strain (BWP17) from others. The ten variations may be due to strain differences or to sequencing of an alternate allele.
In order to maintain viability where a likely essential gene was to be disrupted, a third copy of the ERG27 was placed under the control of the pMAL2 promoter and introduced into the ERG27 heterozygote. The pMAL2 promoter has been used to assess the essential function of other genes in C. albicans. In one case [41] , gene CaDPB2 , a potential homologue to the S. cerevisiae DPB2 gene which encodes the a-subunit of DNA polymerase, was inserted under the control of pMAL2 and a few colonies appeared after several days of growth on glucose. For this gene, basal transcription through the pMAL2 was insufficient to permit growth. PCR analysis showed that the growing cells had regained, by recombination, the wild type gene at the original locus. In another study [24] using the ERG26 gene of C. albicans, 2Á/3% of the cells showed growth on glucose and produce ergosterol. The study concluded that since the only cells able to grow synthesized ergosterol, the ERG26 gene was essential.
Low levels of ergosterol were produced in the erg27 strain grown on glucose. However, the abundant level of early pathway intermediates that also accumulate indicates that recombination of the ERG27 wild type allele under pMAL2 to another locus was occurring in a small number of the cells is the likely explanation for the limited growth. Northern analysis (Fig. 4b) of ERG27 expression from a strain containing the pMAL2-ERG27 construct grown on glucose supports this analysis in that low levels of expression resulting from the uncontrolled expression of the ERG27 gene in a small number of cells is observed. Since growth is not possible without some ergosterol we conclude that the Fig. 5 The sterol profiles of Candida albicans erg27 (NJ61) grown on glucose and maltose, Saccharomyces cerevisiae erg27 (SDG100), and C. albicans wild type (BWP17). SDG100 was provided low levels of ergosterol to allow growth. Ergosterol accumulating in glucose-grown NJ61 is due to low level expression through the pMAL2-ERG27 cassette. A, squalene; B, squalene epoxide; C, squalene dioxide; D, ergosterol.
Erg27p function is essential in this organism. The compounds accumulating in the erg27 strain are nonsterol pathway intermediates, squalene, squalene epoxide, and squalene dioxide. Although differing in proportion, these intermediates are identical to those reported for the erg27 mutant in S. cerevisiae [25] . In contrast, lesions at other steps in the ergosterol pathway lead to the accumulation of sterol intermediates just prior to the mutation. Here, however, there are no C-4 demethylation-defective intermediates in erg27 cells. Instead, no sterols at all accumulate suggesting a regulatory interaction between the 3-keto reductase and lanosterol synthase, the product of the ERG7 gene (Fig. 1) .
Disruption of the ERG11 gene in S. cerevisiae results in non-viability unless a second mutation in the ERG3 gene is also present. This is explained [39, 40] by the formation of toxic sterol diol which accumulates as the result of the attempt of the Erg3p to desaturate the C5-6 position of C14-methyl fecosterol rather than its normal substrate, fecosterol. In the absence of Erg3p function, the lethal diol is not formed thus allowing erg11 erg3 strains to grow. The situation in C. albicans has been less clear because of the exclusive dependence on clinical isolates that may contain other mutations. There have been reports of viable erg11 mutants that accumulate sterol diol [15, 16, 39] . In one study [16] , it was shown that the sterol diol disappeared in the presence of an erg3 mutation indicating a direct role for erg3 in preventing diol formation and indicating that the accumulation of diol reflects the presence of an ERG3 genotype. The erg11 null described here has been shown to have a functional ERG3 gene based on the small accumulation of ergosterol intermediates containing the C-5 double bond and on the presence of significant levels of sterol diol. PCR has confirmed that there are no full-length ERG11 genes in the strain. There have been several reports where increased gene expression of the ERG11 gene has been found to be a mechanism for resistance to the azole antifungals [7] . In addition, inhibitors of one step have also been shown to increase gene expression of several other steps in the pathway [8, 9] . Microarray techniques have recently been employed to assess the regulation of genes in response to itraconazole [9] . In this study, a 2.4-fold increase in ERG27 expression was reported in response to this azole. The availability of a C. albicans erg11 null allows a comparison of azole treatment with a strain in which the Erg11p is absent. Under the azole treatment regimen used here, ERG27 is up-regulated 10-fold. In contrast, expression of ERG27 is increased only about one-third that amount in an erg11 background. Since both itraconazole treatment and an erg11 genotype produce the same sterol profile [3] , this difference in expression may reflect the fact that azoles may have other cellular effects that can influence sterol gene expression. Alternatively, the difference may result from differences in the itraconazole treatment regimens (24 h exposure at 10 mg/l versus the protocol used here.) in the two studies. De Backer et al. [9] using microarray of itraconazole treated cells, found that over 276 non-sterol genes were responsive to itraconazole treatment in addition to the up-regulation of a number of sterol genes. Among these were 140 genes of unknown function. These results support the hypothesis that azoles may have non-sterol pathway targets. Zaragozic acid A, an inhibitor of the early ERG9 step, results in a fivefold increase in ERG27 expression.
ERG27 expression is increased about twofold in the disrupted erg6 and erg24 backgrounds. The data generated from drug treatments and erg gene disruptions support the suggestion that the general upregulation of ergosterol gene expression is the result of ergosterol depletion [8, 9] . In addition, the increase in expression of the ERG27 gene in all backgrounds and treatments applied indicates that it may represent a key regulatory site in the ergosterol biosynthetic pathway.
The results presented here predict that the Erg27p would be a possible candidate for the development of antifungal compounds since this enzyme is required for growth in C. albicans. Further, the fact that the lack of the Erg27p results in a block at ERG7 , in the pre-sterol part of the pathway, means that the cell cannot synthesize any sterol at all. 
